drugset

drugset / Trial / NCT01096979

An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity

NCT01096979 ↗

Phase 2 Completed 60 enrolled Neothetics, Inc

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a double-masked evaluation of the safety and efficacy of LIPO-102 for the reduction of subcutaneous abdominal adiposity.

Timeline

Start: 2009-10
Primary completion: 2010-03
Completion: 2010-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LIPO-102	Unknown	—	Subcutaneous

Indications